Gijs Aertssen: New Evidence on Joint Prosthesis Survival in Inherited Bleeding Disorders
Gijs Aertssen, PHD Candidate at UMC Utrecht, shared on LinkedIn about a recent article he and his colleagues co-authored published in RPTH, adding:
“We present exciting findings on prosthesis survival in people with bleeding disorders: long-term prosthesis survival (up to 25 years) is comparable to that of the general population.
After presenting these results at the EAHAD Congress in Dublin last February, we are pleased to publish the full manuscript in Research and Practice in Thrombosis and Haemostasis (RPTH).”
Title: Long-term prosthesis survival of total hip and total knee arthroplasty in people with inherited bleeding disorders
Authors: Gijs Aertssen, Huub M. de Visser, Wouter Foppen, Roger E. G. Schutgens, Merel A. Timmer, Lize F. D. van Vulpen
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM